🇺🇸 FDA
Pipeline program

Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen.

200908

Phase 2 small_molecule active

Quick answer

Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen. for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
Systemic Lupus Erythematosus
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials